Beleodaq OK'd for Rare Form of NHL

WASHINGTON (MedPage Today) -- The FDA has approved the histone deacetylase inhibitor belinostat for treatment of peripheral T-cell lymphoma, an uncommon but aggressive form of non-Hodgkin's lymphoma (NHL).
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news